ONWARD Medical: A Promising Player in the Spinal Cord Injury Therapy Landscape

ONWARD Medical N.V. (Euronext: ONWD), a medical technology company specializing in innovative spinal cord stimulation therapies, is set to present at the 43rd Annual J.P. Morgan Healthcare Conference on Wednesday, January 15, 2025. The company's CEO, Dave Marver, will provide a company update and participate in a Q&A session, which will be webcast live and archived for 30 days on ONWARD Medical's investor website.

ONWARD Medical is focused on restoring movement, function, and independence in people with spinal cord injury (SCI) and other movement disabilities. The company has developed ARC Therapy, which has been awarded ten Breakthrough Device Designations from the US Food and Drug Administration (FDA). In addition to the ARC-EX System, which is now cleared for commercial sale in the US, the Company is developing an implantable system called ARC-IM with and without an implanted brain-computer interface (BCI).

The company's pipeline of technologies positions it for future growth and innovation. The ARC-IM System is an investigational implantable system designed to deliver targeted, programmed spinal cord stimulation. It has shown positive interim clinical outcomes for improved blood pressure regulation, a component of hemodynamic instability, following SCI. ONWARD Medical is preparing to initiate a global pivotal trial called Empower BP in Q4 2024 to assess the safety and efficacy of ARC-IM Therapy to improve blood pressure regulation.

The ARC-BCI System is an investigational system that uses brain-computer interface (BCI) technology in conjunction with ARC-IM Therapy to restore thought-driven lower limb mobility after SCI. ONWARD Medical has received ten Breakthrough Device Designations (BDDs) from the US Food and Drug Administration (FDA) for its ARC Therapy platforms, including ARC-BCI. These BDDs provide priority FDA review, the opportunity to interact with FDA experts throughout the pre-market regulatory review phase, and the potential to seek additional reimbursement for its ARC-BCI System.

ONWARD Medical's presentation at the J.P. Morgan Healthcare Conference is an opportunity for investors to learn more about the company's innovative therapies, regulatory milestones, and growth prospects. The company's focus on addressing unmet needs in the SCI and movement disabilities space, along with its strong pipeline and regulatory support, sets the stage for continued success. As ONWARD Medical continues to develop its technologies and pursue regulatory approvals, investors can expect to see steady growth and potential stock price appreciation.

In conclusion, ONWARD Medical is a promising player in the spinal cord injury therapy landscape, with a strong pipeline of innovative technologies and a commitment to addressing unmet needs in the market. The company's presentation at the J.P. Morgan Healthcare Conference is an excellent opportunity for investors to learn more about the company's progress and growth prospects.